General MedicationsINJECTIONGeneric
CYTARABINE
CYTARABINE
Standard Dose
100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Key Takeaways
- Primary indication: Review priority: PRIORITY Marketing status: Discontinued
- Approval overview CYTARABINE is listed in Drugs@FDA under application 016793 (NDA).
- Review priority: PRIORITY Marketing status: Discontinued Active ingredient CYTARABINE Form and strength INJECTABLE;INJECTION - 100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor TEVA PARENTERAL Submission history Latest submission status date: 2000-04-03 00:00:00.
Structured Monograph
Clinical summary
Approval overview CYTARABINE is listed in Drugs@FDA under application 016793 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient CYTARABINE Form and strength INJECTABLE;INJECTION - 100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor TEVA PARENTERAL Submission history Latest submission status date: 2000-04-03 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.